Skip to main content

Table 1 Demographic and laboratory data of patients studied

From: Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review

Characteristics

CaC group

AR + CaC group

P value

Number of patients, n

23

85

-

Male, n (%)

14 (61)

55 (65)

0.734

Age, years

66 ± 12

70 ± 12

0.172

Total body weight, kg

56.3 ± 9.3

53.8 ± 12.1

0.362

Dry weight, kg

54.9 ± 9.1

52.3 ± 12.0

0.347

Dialysis time, min

199 ± 27

212 ± 28

0.060

Dose of calcium carbonate, g/day

1.9 ± 1.1

2.5 ± 1.3

0.062

Pre-HD blood urea nitrogen, mg/dL

53.0 ± 13.2

54.2 ± 17.9 [n = 83]

0.771

Pre-HD serum creatinine, mg/dL

7.53 ± 2.24

8.26 ± 2.77

0.246

Pre-HD estimated GFR, mL/min/1.73 m2

6.2 ± 2.0

5.9 ± 2.6

0.561

Serum albumin, g/dL

3.0 ± 0.6 [n = 20]

3.3 ± 0.6 [n = 80]

0.152

Alkaline phosphatase, IU/L

437 ± 336 [n = 10]

304 ± 188 [n = 20]

0.266

Intact parathyroid hormone, pg/mL

25 [n = 1]

93.8 ± 84.7 [n = 14]

-

Post-HD serum inorganic phosphorus, mg/dL

2.3 ± 0.7

2.1 ± 0.7

0.329

Post-HD serum calcium, mg/dL

8.8 ± 0.9 [n = 22]

9.0 ± 0.6 [n = 84]

0.238

Post-HD corrected serum calcium, mg/dL

9.6 ± 1.0 [n = 19]

9.6 ± 0.6 [n = 84]

0.984

Co-morbidities

 Hypertension, n (%)

17 (74)

62 (73)

0.926

 Dyslipidemia, n (%)

2 (9)

16 (19)

0.279

 Type 2 diabetes, n (%)

14 (61)

40 (47)

0.240

 Heart disease, n (%)

8 (35)

40 (47)

0.293

 Peptic ulcer disease, n (%)

0 (0)

6 (7)

-

 Mineral and bone disorder, n (%)

4 (17)

11 (13)

0.626

 Parathyroid disorder, n (%)

5 (22)

8 (9)

0.105

Gastric acid reducers

 Proton pump inhibitors, n (%)

-

73 (86)

-

 Histamine H2 receptor antagonists, n (%)

-

12 (14)

-

Osteoactive drugs

 Vitamin D3 analogues, n (%)

5 (22)

24 (28)

0.533

 Bisphosphonates, n (%)

0 (0)

0 (0)

-

 Calcium sensitizers, n (%)

0 (0)

0 (0)

-

  1. Data are expressed as mean ± standard deviation, or number (percentage)
  2. AR acid reducer, CaC calcium carbonate, GFR glomerular filtration rate, HD hemodialysis